[Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)].
Lordick
F
F
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany. f.lordick@lrz.tum.de
Siewert
J R
JR
D000714:Anastomosis, Surgical; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D002675:Child, Preschool; D003082:Colectomy; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007082:Ileum / Q000098:blood supply* / Q000473:pathology / Q000601:surgery*; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D007511:Ischemia / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000209:etiology; D012307:Risk Factors; D013529:Surgical Wound Dehiscence / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology / Q000601:surgery; D014945:Wound Healing / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab